Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol for prevention of in-stent stenosis after cerebral aneurysm stenting
IRCT20251116068016N1Phase 3Recruiting
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cilostazol in brain aneurysm (IA) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoint: Occurrence of in-stent stenosis following stent placement for cerebral aneurysm. Started Dec 2025; status: recruiting.
02
Drugs
cilostazol
03
Conditions
brain aneurysm (IA)
Beyond the preview
Go deeper on IRCT20251116068016N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251116068016N1.